PRFX

PainReform Ltd. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website ainreform.com
Employees(FY) 6
ISIN IL0011651580

Performance

-0.12%

1W

-25.52%

1M

-62.04%

3M

-59.0%

6M

-70.18%

YTD

-86.39%

1Y

Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Advanced Technical Analysis

Technical Analysis of PRFX 2024-05-10

Overview:

In analyzing the technical indicators for PRFX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.

Trend Anal...

See more ...

Recent News & Updates

2024-05-07 20:30
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com(Globenewswire)
2024-04-18 02:19
PainReform Announces Closing of $4 Million Public Offering(Globenewswire)
2024-04-15 20:00
PainReform Announces Pricing of $4 Million Public Offering(Globenewswire)
2024-04-08 22:30
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions(Yahoo Finance)
2024-04-08 21:00
PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions(Globenewswire)
2024-04-01 22:00
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug(Yahoo Finance)
2024-04-01 20:30
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy(Globenewswire)
2024-02-29 19:00
PainReform Provides Year-End Business Update(Globenewswire)
2024-01-21 19:30
PainReform to Present at the Microcap Conference in Atlantic City(Globenewswire)
2024-01-02 19:30
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief(Globenewswire)
2023-12-26 05:00
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds(Globenewswire)
2023-11-15 03:05
PainReform Provides Business Update for the Third Quarter of 2023(Globenewswire)
2023-09-10 20:30
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File(Yahoo Finance)
2023-09-06 22:00
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary(Yahoo Finance)
2023-09-04 20:30
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City(Yahoo Finance)
2023-08-10 04:05
PainReform Provides Business Update for the Second Quarter of 2023(Yahoo Finance)
2023-08-09 18:45
7 Stocks Under $10 to Buy for August(Yahoo Finance)
2023-07-18 21:00
PainReform Regains Compliance with Nasdaq Continued Listing Requirements(Yahoo Finance)
2023-07-14 02:35
PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement(Yahoo Finance)
2023-07-11 21:05
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement(Yahoo Finance)
2023-07-02 21:01
Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely?(Yahoo Finance)
2023-06-14 20:30
PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st(Yahoo Finance)
2023-06-07 04:30
PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery(Yahoo Finance)
2023-05-17 21:00
PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery(Yahoo Finance)
2023-05-15 04:45
PainReform Provides Business Update for the First Quarter of 2023(Yahoo Finance)
2023-05-01 20:30
PainReform CEO to Present at Aegis Virtual Conference on May 4th(Yahoo Finance)
2023-04-30 20:30
PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery(Yahoo Finance)
2023-04-16 21:00
PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th(Yahoo Finance)
2023-03-27 21:10
PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery(Yahoo Finance)
2023-03-15 20:00
PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy(Yahoo Finance)

Page 1 of 3

previousnext